TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01604343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
Study: NCT04586179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic (treadmill) Exercise
Description: Individuals begin walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion (RPE) greater than 18.5.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic (Agility) Exercise
Description: Participants will begin in a center circle with equidistant cones 2.5 meters away. After the administrator presents a card, the participant touches a corresponding cone and returns to the starting position. Cards will be presented in increasing frequency in synchrony with a metronome application until exercise termination criteria are identified.~Exercise will be terminated if participant a) attains 90 percent of predicted heart rate reserve (HRR=.90\*\[{208-(.7\*age)}-resting HR\]), or b) reports a symptom worsening of 3 or points (0-10 scale) for headache, dizziness, or nausea, d) a rapid progression of complaints with continued exercise, or e) a rating of perceived exertion greater than 18.5.
Study: NCT01797328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cold arm
Description: 1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warm arm
Description: To the best of ability avoid feeling cold during 6 weeks
Study: NCT03627871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Minority Norm
Description: Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minority Norm
Description: Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants receive information about exercise that is unrelated to social norms or trends in social norms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Majority Norm
Description: Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
Study: NCT03305926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up visit M2
Description: Effort test and evaluation at the end of the CVR programme

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up visit M2
Description: Effort test and evaluation at the end of the CVR programme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up vsit M8
Description: Evaluation at 8 months following the CVR programme

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up vsit M8
Description: Evaluation at 8 months following the CVR programme
Study: NCT03544697

Intervention type: PROCEDURE
Intervention: Skin expansion and repair with flaps
Study: NCT04160273

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: patient questionnaire and telephone follow-up
Description: PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
Study: NCT00778193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: 1 tablet 500mg BID for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1 tablet 81mg QD for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 1 capsule 200mg QD for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule BID for 8 days
Study: NCT05517746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration
Study: NCT00643968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV+TDF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV+3TC+TDF
Study: NCT04037202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot massage
Description: Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
Study: NCT03242499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Lovastatin 80mg or placebo use for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for 48 weeks
Study: NCT00554827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate.
Study: NCT05517746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration
Study: NCT00554827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride). Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or
Study: NCT03140202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRmeter (feedback device) with feedback
Description: Participants have a real time feedback and record.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRmeter (feedback device) with feedback
Description: Participants have a real time feedback and record.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRmeter (feedback device) without feedback
Description: Participants have a real time record without feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRmeter (feedback device) without feedback
Description: Participants have a real time record without feedback.
Study: NCT04607226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Description: respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Description: respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Description: respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous vagus nerve stimulation
Description: respiratory-gated non-painful electrical stimulation of the auricle for 30 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation
Description: stimulation of the auricle for 30 minutes
Study: NCT03382990

Intervention type: DEVICE
Intervention: DES or BMS
Description: DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.

Intervention type: DEVICE
Intervention: DES or BMS
Description: DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
Study: NCT03083496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Oxalate 5%
Description: Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
Study: NCT02447614

Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: Adenotonsillectomy

Intervention type: OTHER
Intervention: Conservative treatment
Description: Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists

Intervention type: OTHER
Intervention: no treatment
Description: just regular follow-up
Study: NCT02687464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Description: will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study.
Study: NCT03083496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Oxalate 5%
Description: Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Oxalate 10%
Description: Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
Study: NCT05517746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 tablet
Description: tablets, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2395840 oral solution
Description: solution, oral administration
Study: NCT03083496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Oxalate 10%
Description: Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
Study: NCT04176003

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies

Intervention type: OTHER
Intervention: Member checking
Description: Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.

Intervention type: OTHER
Intervention: Member checking
Description: Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.

Intervention type: OTHER
Intervention: Member checking
Description: Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
Study: NCT01768390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothpaste containing 5,000 ppm fluoride
Description: 1 cm tootpaste twice daily during 2 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1450 GCP
Description: Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
Study: NCT04900077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere® Motion™ Appliance
Description: class II malocclusion corrector
Study: NCT01458288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-0054
Description: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
Study: NCT04548674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35%
Description: Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35%
Description: Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
Study: NCT05517746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo matching BAY2395840, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo matching BAY2395840, oral administration
Study: NCT04548674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35%
Description: Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whiteness HP 35%
Description: Single application of 45 minutes on the buccal surfaces of third molars, with an average thickness of 1 mm
Study: NCT05517746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo matching BAY2395840, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo matching BAY2395840, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo matching BAY2395840, oral administration
Study: NCT01079169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Description: Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry capsules
Description: Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
Study: NCT04548674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35% + LASER
Description: A dose of LASER (60 J / cm2, for 16 seconds) was applied at two points, one point in the cervical region and another in the center of the buccal surface of the third molars, using visible infrared LASER therapy (Photon III / DMC, São Carlos, SP, Brazil), with a wavelength of 808 nm, and AsGaAl, as an active medium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35% + CPP
Description: Topical application of casein phosphopeptide amorphous calcium phosphate fluoride CPP-ACPF (My Paste Plus, Recaldent, GC, USA) with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whiteness HP 35% + NANO
Description: A topical application of nanohydroxyapatite (Nano P FGM, SC, Brazil) was performed with the aid of a microbrush (KG Sorensen, SP, Brazil) in a passive way for 5 minutes after teeth whitening.
Study: NCT05112224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program based on health belief model to improve oral health
Description: Five weekly sessions each one lasted for one hour to encourage participants to follow healthy behaviors on oral health.
Study: NCT00103376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-RH Agonist
Description: given as a 3 month depo-injection
Study: NCT02605668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified psychological intervention
Description: 12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: 12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
Study: NCT05385939

Intervention type: OTHER
Intervention: Observational
Description: This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.

Intervention type: OTHER
Intervention: Observational
Description: This was an observational study which involved collection of stool samples and environmental samples at 1 week and 4 weeks of life.
Study: NCT00103376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Receptor Antagonists
Description: given orally daily for 3 months
Study: NCT03909009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS + Neuronavigation
Description: Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS + Neuronavigation
Description: Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
Study: NCT02075944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic exercise
Study: NCT01103375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative study
Study: NCT00320073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 75 mg to 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Pemetrexed is administered intravenously over 10 minutes, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
Study: NCT00726882

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection only
Description: Approximately monthly collection of blood samples.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Previous treatment in prior ABT-333 studies.
Study: NCT00247416

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 16 mg bid for 4 days prior to each chemotherapy start.

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 6.0 intravenously over 30 minutes on day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6.0 intravenously over 30 minutes on day 5.